Tags : NVX‑CoV2373

Novavax Initiates P-I/II Study of NVX‑CoV2373 Vaccine Against COVID-19

Shots: The company reported the enrollment of the first participants in a P-I/II clinical study of its vaccine candidate, NVX‑CoV2373, developed utilizing nanoparticle technology. The vaccine includes Novavax’ Matrix‑M adjuvant to enhance immune responses and stimulate high levels of neutralizing Abs with its expected preliminary immunogenicity and safety results in Jul’2020 The P-I-part evaluates the […]Read More